<SEC-DOCUMENT>0001437749-21-011756.txt : 20210512
<SEC-HEADER>0001437749-21-011756.hdr.sgml : 20210512
<ACCEPTANCE-DATETIME>20210512073520
ACCESSION NUMBER:		0001437749-21-011756
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210512
DATE AS OF CHANGE:		20210512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		21913463

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbrx20210426_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:mbrx="http://www.mbrx.com/20210512"><head><!--Created on 4/26/2021 1:01:48 PM -->
	<title>mbrx20210426_8k.htm</title>


<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20218K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20218K" name="dei:EntityCentralIndexKey">0001659617</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="mbrx-20210512.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20218K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001659617</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-05-12</xbrli:startDate>
<xbrli:endDate>2021-05-12</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>FORM <ix:nonNumeric contextRef="d20218K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): <ix:nonNumeric contextRef="d20218K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>May 12, 2021</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="text-align: center;"><img alt="moleculinlogoresizedclear.jpg" src="moleculinlogoresizedclear.jpg" /></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityRegistrantName"><b>MOLECULIN BIOTECH, INC.</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">(Exact Name of Registrant as Specified in its Charter)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:8.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="text-transform:uppercase;">delaware</span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:8.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityFileNumber"><b>001-37758</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:8.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityTaxIdentificationNumber"><b>47-4671997</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation or Organization)</div>
			</td>
			<td style="vertical-align:top;width:8.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission File No.)</div>
			</td>
			<td style="vertical-align:top;width:8.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressAddressLine1"><b>5300 Memorial Drive</b></ix:nonNumeric><b>, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressAddressLine2"><b>Suite 950</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressCityOrTown"><b>Houston</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressStateOrProvince"><b>TX</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressPostalZipCode"><b>77007</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">(Address of principal executive offices and zip code)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>(<ix:nonNumeric contextRef="d20218K" name="dei:CityAreaCode"><b>713</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20218K" name="dei:LocalPhoneNumber"><b>300-5160</b></ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">(Registrant&#8217;s telephone number, including area code)</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">(Former name or former address, if changed from last report)</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:24.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#xa0; Emerging growth company <ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:8.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading Symbol (s)</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:8.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:8.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $.001 per share</div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20218K" name="dei:TradingSymbol">MBRX</ix:nonNumeric></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:8.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20218K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 2.02</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Results of Operations and Financial Condition.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">On May&#xa0;12, 2021, Moleculin Biotech, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended March 31, 2021&#xa0;and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Item 9.01 </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(d)&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Exhibits.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:6.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit No. </b></div>
			</td>
			<td style="vertical-align:top;width:0%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:6.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_243845.htm" style="-sec-extract:exhibit;">99.1</a></div>
			</td>
			<td style="vertical-align:top;width:0%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_243845.htm" style="-sec-extract:exhibit;">Press Release dated May 12, 2021</a></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:6.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:0%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cover page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b><span style="text-decoration: underline;">SIGNATURE</span></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
			<td style="vertical-align:middle;width:12.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MOLECULIN BIOTECH, INC.</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
			<td style="vertical-align:middle;width:12.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: May 12, 2021</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
			<td style="vertical-align:middle;width:12.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By: <span style="text-decoration: underline;">/s/ Jonathan P. Foster</span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.2%;">&#xa0;</td>
			<td style="vertical-align:middle;width:12.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jonathan P. Foster</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Financial Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;">2</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_243845.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 4/26/2021 1:06:07 PM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>ex_243845.htm</title>

</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 16pt;"><b>Exhibit 99.1</b></p>

<div><img alt="moleculinlogoresizedclear.jpg" src="moleculinlogoresizedclear.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>- Multiple ongoing clinical studies expected to drive key clinical and regulatory milestones throughout next 18 months -</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>- Significantly strengthened financial position extends cash runway through 2023 - </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>HOUSTON, May 12, 2021 /PRNewswire/ -- </b><b>Moleculin Biotech, Inc.</b>, (Nasdaq: MBRX) (Moleculin&nbsp;or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended March 31, 2021. The Company also provided an update on its portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&#8220;Over the course of the first quarter, we continued to make significant progress on multiple fronts. Importantly, we have equipped the Company with the resources to advance our portfolio of drug candidates across a number of oncology indications and viruses. On the clinical front, we have the potential to see up to seven clinical trials this year, including investigator sponsored trials. We believe we are well-positioned to execute our strategy and expect to continue to build momentum and drive shareholder value in the near- and long-term," commented Walter Klemp, Chairman and CEO of Moleculin.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Recent Highlights </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Granted Rare Pediatric Disease Designation (RPD) from the U.S. Food and Drug Administration (FDA) to its p-STAT3 inhibitor, WP1066, for the treatment of ependymoma, increasing to a total of four different indications for which a Priority Review Voucher may be granted;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Engaged IQVIA Biotech to manage Moleculin&#8217;s effort to begin potential clinical trials of WP1122 for the treatment of COVID-19;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Received Fast Track Designation from the FDA for its drug, Annamycin, for the treatment of soft tissue sarcoma (STS) lung metastases;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Announced a $1.5 million&nbsp;grant was awarded to the Maria Sklodowska-Curie National Research Institute to fund an investigator-initiated Phase 1B/2 clinical trial of Annamycin for the treatment of STS lung metastases;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Successfully closed a public offering, including full exercise of over-allotment option, for gross proceeds of approximately $78.0 million, before deducting underwriting discount and offering expenses;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Announced 100% survival achieved in preclinical study in animals which demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Signed an agreement with Catalyst Clinical Research to manage its U.S. clinical trial to study the ability of Annamycin to treat STS that has metastasized to the lungs.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Programs Update </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Next Generation Anthracycline - Annamycin</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Annamycin is the Company&#8217;s "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin (the standard of care chemotherapy for STS lung metastases). Importantly, Annamycin has also demonstrated a lack of cardiotoxicity in recently conducted human clinical trials for the treatment of acute myeloid leukemia (AML), so we believe that the use of Annamycin may not face the same usage limitations imposed on doxorubicin. Annamycin is currently in development for the treatment of&nbsp;AML&nbsp;and STS lung metastases.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Upcoming Milestones</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2H 2021: Report topline results from ongoing Phase 1/2 study for treatment of AML.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2H 2021: Commence Phase 1/2 study in Europe for the treatment of AML evaluating combination therapy of Annamycin + Ara-C.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2H 2021: Commence&nbsp;Phase 1b/2 clinical trial of Annamycin for the treatment of STS lung metastases in the U.S.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2021: Based on recently announced reimbursement grant&nbsp;awarded in Poland, the Company expects a second Phase 1b/2 clinical trial of Annamycin in sarcoma lung metastases to be primarily investigator-funded in Europe.</p>
			</td>
		</tr>

</table>

<p style="text-align: left; text-indent: 0pt; margin: 0pt 0pt 0pt 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="text-align: left; text-indent: 0pt; margin: 0pt 0pt 0pt 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>First-in-class p-STAT3 inhibitors - WP1066 and WP1220</b></p>

<p style="text-align: left; text-indent: 0pt; margin: 0pt 0pt 0pt 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">WP1066 is one of several Immune/Transcription Modulators, designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3 (phosphorylated signal transducer and activator of transcription 3), c-Myc (a cellular signal transducer named after a homologous avian virus called Myelocytomatosis) and HIF-1&#945; (hypoxia inducible factor 1&#945;). These transcription factors are widely sought targets that are believed to contribute to an increase in cell survival and proliferation, and the angiogenesis (coopting vasculature for blood supply), invasion, metastasis and inflammation associated with tumors. They may also play a role in the inability of immune checkpoint inhibitors to affect more resistant tumors. WP1220 is a close analog to WP1066 that the Company has developed as a potential topical therapy for skin-related diseases.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">WP1220 is currently being evaluated for the treatment of Cutaneous T-Cell Lymphoma (CTCL) and WP1066 is currently being evaluated for the treatment of pediatric brain tumors, including Diffuse Interstitial Pontine Glioma (DIPG). Additionally, WP1066 + radiation is being evaluated in the treatment of treatment of Glioblastoma Multiforme (GBM).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Upcoming Milestones</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2H 2021: Facilitate&nbsp;Phase 1/2 study of WP1066 + radiation for the treatment of GBM.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1H 2022: Facilitate&nbsp;launch of Phase 2 study of WP1066 for the treatment of pediatric brain tumors, including DIPG.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Actively seeking collaboration with a strategic partner in the near term for external funding for the continued development of WP1220 in a Phase 2 clinical trial as a topical therapy for CTCL.</p>
			</td>
		</tr>

</table>

<p style="text-align: left; text-indent: 0pt; margin: 0pt 0pt 0pt 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&nbsp;</p>

<p style="text-align: left; text-indent: 0pt; margin: 0pt 0pt 0pt 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>Infectious Disease and Metabolism/Glycosylation Inhibitors- WP1122, WP1096 and WP1097 Portfolio</b></p>

<p style="text-align: left; text-indent: 0pt; margin: 0pt 0pt 0pt 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&nbsp;</p>

<p style="text-indent: 0pt; margin: 0pt 0pt 0pt 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: justify;">Moleculin has new compounds designed to target the roles of glycolysis and glycosylation in both cancer and viral diseases. The Company&#8217;s lead Metabolism/Glycosylation Inhibitor, WP1122, is a prodrug of 2-DG that appears to improve the drug-like properties of 2-DG by increasing its circulation time and improving tissue/organ distribution.&nbsp;Recent published research has identified that 2-DG has antiviral potential against SARS-CoV-2 <i>in vitro</i> and, based on publicly available information, a recently completed Phase 2 clinical trial by an unrelated company in India has reported&nbsp;efficacy in COVID-19 patients, resulting in the Emergency Use Authorization of 2-DG by the Drugs Controller General of India. Moleculin believes that the improved drug-like properties of WP1122 may allow it to outperform 2-DG in COVID-19 patients and may provide&nbsp;the opportunity for it to become an important drug to potentiate existing therapies, including checkpoint inhibitors. Although the Company has seen superior efficacy for WP1122 over 2-DG against SARS-CoV-2 in vitro, as well as in multiple animal tumor models, WP1122 has yet to be tested in humans so there can be no assurance that this improved preclinical performance will translate into improved clinical outcomes. The Company is also engaged in preclinical development of additional antimetabolites (WP1096 and WP1097) targeting glycolysis and glycosylation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Upcoming Milestones</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2H 2021: Seek to initiate Phase 1a/1b study of WP1122 for the treatment of COVID-19.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2H 2021: Potential to launch Phase 2 pivotal study of WP1122 for the treatment of COVID-19.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2H 2021: File an IND in the U.S. for the treatment of certain cancers such as GBM and pancreatic cancer, with WP1122.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:40pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ongoing preclinical development work in anti-viral indications such as HIV, Zika, and Dengue. IND targeted for 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Summary of Financial Results for First Quarter 2021</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Research and development expense was $4.1 million and $3.2 million for the three months ended March 31, 2021 and 2020, respectively. The increase of $0.9 million is mainly related to increased clinical trial activity as described above, increased costs related to sponsored research agreements, and costs related to manufacturing of additional drug product.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">General and administrative expense was $1.9 million and $1.8 million for the three months ended March 31, 2021 and 2020, respectively. The increase of $0.1 million is mainly related to an increase in the Company&#8217;s insurance, which was offset by a similar decrease in travel expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">For the three months ended March 31, 2021 and 2020, the Company reported a net loss of $4.4 million and $1.2 million, respectively, and had net cash flows used in operating activities of $ 3.6 million and $4.3 million, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">The Company ended the quarter with approximately $86.3 million of cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>About Moleculin Biotech, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a next-generation anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">For more information about the Company, please visit http://www.moleculin.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Forward-Looking Statements </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the announcement of the results of our clinical trials; our ability to commence new clinical trials for Annamycin for the treatment of AML and STS lung metastases; our ability to commence new clinical trials for WP1066 for the treatment of GBM and DIPG; our ability to commence new clinical trials for WP1122 for the treatment of COVID-19; whether investigator-funded trials will proceed as expected; our ability to find collaboration partners for the continued development of WP1220 for CTCL; our ability to file an IND in the U.S. for the treatment of certain cancers with WP1122; and our ability to file an IND in anti-viral indications such as HIV, Zika, and Dengue.&nbsp;Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.&nbsp; Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Investor Contact:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">JTC Team, LLC</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Jenene Thomas</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(833) 475-8247</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">MBRX@jtcir.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 16pt;"><b>-- Financial Tables Follow--</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:18.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Moleculin Biotech, Inc.</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Unaudited Condensed Consolidated Balance Sheets</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(in thousands)</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>March 31, 2021</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>December 31, 2020</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current assets:</p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash and cash equivalents</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">86,293</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">15,173</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prepaid expenses and other current assets</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,726</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,025</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total current assets</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">88,019</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,198</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furniture and equipment, net</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">438</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">483</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Intangible assets</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,148</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,148</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating lease right-of-use asset</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">179</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">202</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">99,784</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29,031</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current liabilities:</p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounts payable and accrued expenses and other current liabilities</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4,578</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,920</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total current liabilities</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4,578</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,920</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating lease liability - long-term, net of current portion</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">127</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">159</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Warrant liability - long term</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,563</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,192</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total liabilities</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,268</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,271</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders' equity</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">88,516</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,760</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">99,784</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29,031</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Unaudited Condensed Consolidated Statements of Operations</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="6" style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="6" style="vertical-align: bottom; width: 0%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Three Months Ended March</b>&nbsp;<b>31,</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(in thousands, except share and per share amounts)</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2020</b></p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenues</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">&#8212;</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating expenses:</p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Research and development</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4,105</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3,206</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">General and administrative and depreciation</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,983</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,856</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 9pt;">Total operating expenses</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,088</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,062</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Loss from operations</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(6,088</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(5,062</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income:</p>
			</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Gain from change in fair value of warrant liability</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,577</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3,845</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Other income, net</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">9</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Interest income, net</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">57</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss</p>
			</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(4,445</p>
			</td>
			<td style="vertical-align:middle;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:middle;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(1,209</p>
			</td>
			<td style="vertical-align:middle;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss per common share - basic and diluted</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(0.20</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p>
			</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(0.15</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:0%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Weighted average common shares outstanding - basic and diluted</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21,808,565</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="border-bottom:double 3px #000000;vertical-align:bottom;width:2.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,321,833</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mbrx-20210512.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 5/11/2021 5:25:16 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:mbrx="http://www.mbrx.com/20210512" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mbrx.com/20210512">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20210512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20210512_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mbrx-20210512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.mbrx.com/20210512/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="mbrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>mbrx-20210512_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 5/11/2021 5:25:16 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.mbrx.com/20210512/role/statement-document-and-entity-information" xlink:href="mbrx-20210512.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.mbrx.com/20210512/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mbrx-20210512_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 5/11/2021 5:25:16 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line Two</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Ex Transition Period</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mbrx-20210512_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 5/11/2021 5:25:16 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.mbrx.com/20210512/role/statement-document-and-entity-information" xlink:href="mbrx-20210512.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.mbrx.com/20210512/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>moleculinlogoresizedclear.jpg
<TEXT>
begin 644 moleculinlogoresizedclear.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0"L17AI9@  34T *@    @ !0$2  ,
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M>'!A8VME="!E;F0](G<B/SX _^T .%!H;W1O<VAO<" S+C  .$))300$
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M_C+3AQ)X#5LVS-)XY8'+\:GHK5Y?5>9I+176+KQLE9*5DDDD?P1X.TO]5_I
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MQ.(KU(=I5)R7W.37]?=G2P6#HRYJ-*G"7>,8I_@E_7X]O7 =(4 % !0 4 %
B!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>mbrx20210426_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbrx-20210512.xsd" xlink:type="simple"/>
    <context id="d20218K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001659617</identifier>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20218K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20218K">0001659617</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20218K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20218K">2021-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20218K">MOLECULIN BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20218K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20218K">001-37758</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20218K">47-4671997</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20218K">5300 Memorial Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="d20218K">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="d20218K">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20218K">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20218K">77007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20218K">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20218K">300-5160</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20218K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20218K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20218K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20218K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="d20218K">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="d20218K">true</dei:EntityExTransitionPeriod>
    <dei:Security12bTitle contextRef="d20218K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20218K">MBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20218K">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140434381480056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">MOLECULIN BIOTECH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">May 12,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">47-4671997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">5300 Memorial Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity, Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">77007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-5160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity, Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001659617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MH,GJ>.0_/ABYS8[92VG@T)[=;A@%M[(%X/M*2O/^8$_N^1\OO?\ 4$L#!!0
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MDUM)Z.#<@V#OX96,'<V/'W?W U!+ P04    " !I/*Q2)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ :3RL4F60>9(9 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( &D\K%(%;]9\[P   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ :3RL4CJJHN=  0  / (   \
M     ( !9Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &D\K%(D'INB
MK0   /@!   :              "  =01  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( &D\K%)ED'F2&0$  ,\#   3
M  "  ;D2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(   ,4
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbrx20210426_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbrx.com/20210512/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mbrx20210426_8k.htm">mbrx20210426_8k.htm</File>
    <File>ex_243845.htm</File>
    <File>mbrx-20210512.xsd</File>
    <File>mbrx-20210512_def.xml</File>
    <File>mbrx-20210512_lab.xml</File>
    <File>mbrx-20210512_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moleculinlogoresizedclear.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mbrx20210426_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "mbrx-20210512_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mbrx20210426_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbrx-20210512_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbrx-20210512_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mbrx-20210512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 28,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mbrx",
   "nsuri": "http://www.mbrx.com/20210512",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20210426_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.mbrx.com/20210512/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "mbrx20210426_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity, Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity, Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mbrx.com/20210512/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-21-011756-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-21-011756-xbrl.zip
M4$L#!!0    ( &D\K%)<I89DIQT  " L 0 -    97A?,C0S.#0U+FAT;>T]
M:U?CN)*?;_\*+=-W&LXZ(0GOQ_19&FB:G::;"_3,GOVR1[&51(-M>20;.O?7
M;U5)CIT07MT0DN![9X;$D62I5*IWE79[:12^W^T)'KS?C43*F=_CVHCTMX4L
M[=0V%]S3F$?BMX6.TA%/:X%(A9]*%2\P7\6IB*%U*D*1]%0L?HL5=/J/6FU?
M"YZ*@*F8K2ZWUI=;C5:3-;<;Z]N-#79ZPFJUH;&[(A::ITJ7!CT[.&*?+DX^
MLWT57PF="LU6ZJOUE7ICX?V;?^RF,@W%>_']_UJK*YNK:W58R^ZR??CF'V]V
MEVE5;W;;*N@SD_9#6D&<UHS\M]AFS4:2[C!ZT.&1#/O;[->_,Y7N7,A(&/9%
M7+,S%?'8/MQA"0\"&7>W64/&K%%ORGB'^9DV2F\SGJ5J!^:TFPR]R(T[,N!.
M,0F: WV]XEKR.-V.$<3A3BJ^IS4>RFZ\K66WE^Y$7'=EO WM6?YO<QTZ ZS;
M[P^_]V1;IFQKJ][<76Z_WUU.WK]YLQO(J_>[,NHR'@(P(Q4*/PME'*JNT@+?
M'_BAX+K^5])=8$;[][6!<7'(-[<L\]W(.M\]9*'%NF IO\9MD^RXV3\6E*W[
M0>D#5@D]#I:;4_%^V,J3? ?8F4B43@W[*+5)V;\R3OA/I^BCC'GL2QY"(Y.%
MT(C' 3O5ZDH&,#WXT-4\,NQ;$L 1+&'$K,'T <?C7IC*]S5V D"222B &'45
M'&+F X2E#P T:19(>+WXG@!- W*5*A9H>278I>@7S1"^6G2S$"E4G\&\A4F!
MVAF6]K3*NCV5I2R&6;'F)HM@QCW#:KO+\D<!_P0+GPK GT-+V0$0QFF(1%B+
MN)OV@-0'K#- XD09B>P$-@'H?F"8STV/Z2R^YOT<OHCX*ZS&[H/I"Q.A!\#M
MK\RDLM._DPI\^OKM_.+K%X^=  2:+<\>^^73,WBIN99:+ /[9'2PRR3C@U3
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M6J"+[T &4@L&(,NPXFZ?EF(9(3;)-PD_MS,9!L#8$.>SB!I:+FF /(B>"@.
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M&,C-G<GZ;CR<8X/<B ]UTN:X%UKU%_1@'ME(#%1T]N*T!]I/'Y%-L%J!3:\
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MOYN$2XB1AZF*2:BX)+B7Y#?O6(A$'LA*"8X6H;YY>YBG;GE!Q[L*6ED2N8?
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M\N)@RK^2!"O^_O%<HC[4W_WQSM]02P,$%     @ :3RL4J#!7AL:#@  -5<
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M;7=SS"A:UT2KO]YS'H]SSB&T_!051%\"ITL)?%/O&I82>A\?Z(_X9([S%\5
M+W^8R3V9NZ<I?<^RZDO0U3(O6=^YZS1 1$JX4&OA5X3CL2P%-!)8J:2]!)(G
MV7=D&1>^XCIC54.=)K*\QQ@IO!>QTH^ZM%#.EVS(^4NSUU%LCV^;DW<L>/\-
MQ"SQ")K*7I"9E8!*!?5 C9B4/( ^::9I?!^RHD5+7!^/*SJ0+:\.?8&8O?"R
M[7;:V$O>MZ4!7GRG=LY7U6#1<!VS\6KD<]3EO?@W3Y1:&"F.CL![@WM]Q@2;
M=S7#"%42HT'+2",'=ETUU1CKXZ8YF_?^%I](_8TXBE1B<[+635^O2XMXO3S7
MM.'XM'5\*%I<5W2FZ'Z.BQ-;G%%/>+_%N&UQ,76O%7Q7@ 4^5B5GX:?0^MA2
M]#TO/,]&+\#[DEXNO"=03!WBEP KBBO('8H:-MRKNAPJL$)9;F%X*E#+^+?S
M@"N ^W3_0X.D?3^MI;,$GVD@P61+LX#L-(U/WO0ACB*<20-=<B9\3EJD>S5V
MX+:R%^'\[14FBTBN#;LZ3T<7:(:%>U78U7YF[67;UOJZ6I7R],Q?8-:=/*;2
MY-"66.Y:G6ABGZIV2D#[HABZ<"@A_&)0L9T_AE/ GV,_Q8J<I]I%\@+5+S4R
MQV#,8XL["L=*MF)PP,-CRVWU0(PQ@U'O7%HHAQG%@VA"N;9%0,4^G2LC,>XW
MGA13= @^?.3FGS)N';W$<=W:4>4P$[NWMI]^!J%>(J_([!6C+AM==F92T'VW
M1FIEN+@0)ZY]!_7];<Q0_J4T9ZPKZ.SKP?<9SJF)P!)CTP3G01W6Z,#16Q0S
MXR9K"2U8OYFWR>$*XR_'8A3!8YDJZ*9<H9XGF7/=!H^G/QY!*:&A;+Q)93(C
ML.J8#^]2ER(?C@CME\4@%R)01),F]K%K888XZ%6*O;1[T<'3[<XRO@D#18#J
M+3NR]C&.U_^J9HJ(Z=JP0.[#YM1PJ8>2ZD/M#]Q%]Z,9686;@YS-H,^02T<J
MC*MXO!4'*Q^H_$U1D>1X'I ]FP;X*GG;\\?KTB(:H)41O)![% GD1.'F7_)R
M-"PXP,!\S9*-%:D4PZL5!"^GP3]!^$5G<E!;\I!]1Y'_,C:AS6(G@_[286>:
MP P-L/#+9'4;KQ,1!3H/%YOFB:<!IHL-=[34R14TP(4?%,&1TFK&Y!?0*M9V
MUHM0H_K27] X?CYB5SN2^5M4A'+4[%B4YP*4P\!35.[>N.H#OWH^)H'O_F!T
M%]O]G)OMH4X<' 8^($U(W=-,ZJ./&V8F%*7%'V,K*^HM@T*1F#[[Z%TF)XXK
MZQ(B=DJDRQYK.P:%@Z7BL^YH.RN8HX&L^1SRX:.39K"S -OJ?.7\%NS]#.7)
MR=MJSQ_?FZ^%#SJ=&]L#QC(3GYG5-5P]4HVA"MI[6 5#+RN5135\Z>53.0BI
MJ:VA7LU-%QFY9O@@D ;((/&&<\$S([$="&93UQQG8Q YX;R'W[L*/]/&=>>E
M2Y#("KE*_TA7(T)*HWC1^F@S#M>@)0H/LN,#=@YFP-HJ"Q=CNH:P&GMR.[EZ
M[TW8+G58)UW'</*T/"EO888,L*2MA:^>S:(^ ;\_\P<#X'1!_N\;,&WP]U1;
MVHY'UM1NOB:*KDX@'$X^-%^&"UC_[<>J1DN2DC5)5 B_#_<QJ6\>=TS+>6"_
MDA, =7U%#NT"F;!ZOG)5CY:,L1U^KVKT= 1V&S'_[=!A(PFN&B.V63DS3!=9
M0IB*LONUJ)*Q=;OW;:E5]\_&Y%=[ F09#(7CF<F7K"%P4D,S]D=]XJ<JDXAY
MGB#["UH54#LRY]:* W]ANX#=\1%47X!;RMR2WYHAQ+J*!%<S7.%Y>"6S#[A+
MV4?>1=$O6@6^S]9(8ND;QCU<UZ::1]%?>MI1O?M]&\1% YP_O>$O LA+A!B3
M$RSHTCL'0[&T&^0(-P(R.J$L]XL3E-_=[GS1]=EO?X1?1S1V?45>W>EMF.27
M+8(<X(Y!$!J@AP-[1 -D%J?!E_ J(?0@_M 7,5*PHI\VC[."0Y($E;*F@TNG
M#:';J$ODZ=8YS<$%$OUSBC6^A7M5%9+L54JV=A@&Z13T)WT9_# 2F%W<JV_E
MI#\ S73QIP0[.N(#&)3='S[<B[H+87>J2#$2P.#]WMP+XHQMM<38LXH$B1M
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MM>][6_;MO%GYKOR&'\FA!6U= L'#L#_5RFJ.-%QM-'B<@MYT@K=L^D7;A['
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M 2&!WPJ?;G72'!(B+J>-JS2@"V[[E(K9C'G:+GZ!FLL-J%U;8\9O*A35?Q0
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M)X8)F9VE3VF CJ/M6-!9//J41[:SGB57ME&E27^KI@Y_K]Y2V,8W?]@EV]$
MCL^W[99=8"(YM1Q2M^S34P3*20%M/\^1&!71G;VQY3S!5Y4DALO ,.TFC:HU
M1SVTNCY[RS/>X!AAB[21AZ,?9UR)<ZSD9 *0SE5A(<>'9=DV3]828_9BW[(0
MDK:^4VN,T;HJ81JD_G'=8'<X;88W70W;U0J2(@KL]_S^313C=(;\G#2],-">
M/7]58&H7CTG4$H57MJ*8F@4W4,PR912=4R;#2(ZP:/A.@3GCLU$,O7@31AM/
M>5O-'JB!E]O57&%_XV7ZM]3\ZQU:UZV(UIQIOLTN$=&,Q_0<^JR09C%F)D.+
MM=%(%PW9HN(MCQ[VK&3!M%F;NDY)"..2;PX'(1?,5P[2Z7C#6^V)?(+?&"N.
MSH_%1COL)"N]MQQ.5QM&<W$K2[YL4W(\K,*:3[9XT #/YZ\I)Y.E@^L7<X46
MNCJO6[?J[S><Y"I'DI(RB2B"+ ;/HQ2F83+Y:_WIMW#I<F)'5W3VW:'.Y*#]
MXK+JPZOS;IG?7'?F??I]54]AG<#J 5,9VYNED5W@)E\G?Z=-(\@SH/=8_U\@
M$I0SM)PLB?CS6%8=SR_><7(3ZV;CT'+-7-+VXP6G,24I2*8PLG)F9<OB^BF&
M9&B<&8YW^'*K*VN%<E5H(;FSC!?9J@\R): N4'C)K8NL3+EG%]@QL92;1 Q!
M+(X"EEJS<I\J\//,NTX<PQ9TRV:5@'YQ>,?G ^ E% #!^UHO0BCZK,(W?XJ*
M\E@7]6>-%"L$TYP2\0-KI5B5506502VADF<DV@\Q<2.5#F6R703_HT"BS @Z
MNLP*W("5L#C #F<U"HYD-<T-FJ43BI&M7EH7$%[DB., >+P#4:RU+'Y.Z3OT
ME JT9M_=VZ:G2) 3";,,]M,7$2[[&]Q[94QD%YNAJ:,_'3I6=)9?"K+++B@H
MU@[6QJEYBA$)>=>4?T<F\5BMMMN>,P:M92L-EJZ7'(VL=^V5@HP%!T\;@]&L
MYTA0#K^XTM=+Y!GCZPN^&WD9_$TV ;?'_9.5)8/84U:B4Y9:5)(-[(_B3JJ4
M'%V@)S$M,!J =?6I,;9DHZ%KLX_D9C 4:"1DU#P:E&MBT4SV*;&S76OP3L78
MSWK81>>'! EV<3;*&RA]EK.P>DA'E2&N<,2TP5-37.0M;YHPFJBW&0?DY%_4
MDV^_W6.6DY7P,,6KQTA7)'CH"W2B6?A!A6UR=/U/Z N,QINI0UF%G)O<]1#S
M/-X"%^Y.B1XS?YAPJM=J:K#^0BWEVAHQGM"%@R: JUS'VZ%1+1Q: E,>8 8M
MWLFUVN9;Y(#%Y'.V'B$9S:JD]+[1CV]#"-NLJZ_6554R#N1!%6V.!(,KY711
M2.,3R;J(F_T[3SZH:]TZ'X]E\I8T2V329?@I,8@KK)=4EO3_.)+B_SDXN"FW
M)8<:YR#3#E(^P9AHMA+*&T?D2/'%>M6<8KQO7AKH3VMG9TKFR(YXE98%;IW<
M'R?=/DE TD9_OS4S0)6@2)'#2&5?M<3(4)))6Y9)(H)^\;J*D52[%M_8 T7;
M>;O*D@H-#5"(BO6^M7S!?NW]4S53OJ"\X6X<;J0[H&0\)@"B/F;H]%% $==G
MG'OW%@2X RON- U)^##S*,N+W]LG=>DMU=Y>K-_=O-WU3:S:"$89WAV>>$NM
MV[;3P$!IR//PW.\_WD8*7-?BV-#H2J !7/\,8DTZ74]6ZO-V6"\)[\M17(GI
M^0A"YX;)ETR3H69A._NK#)DU[-,>*3?.V$N]K9T!'XQ'ST-8KO7[CNS,J2[U
M!L1VB-D-P2%E#7YF>3Q-,V(\0RTXLS29\Q1Z F80K(9[N+Y,N81X?,;??U_5
MD(WY&I(OGTEWRL  DFYDG^-IO(N,U)(ANL4ASI88X6F Z^Z\ \_WIKW%!A%^
M!1YY]&."M^)>35G';U9IZD>;*0@*"965[;% LUT/:ZX_W"FJ(ME8_<J]I-<(
M)DK*%H0?G!+:0R[%A3G!;E(RW1M\T?V.0@DURX1"2/\^HGH18O(X-[72[E?+
M>BV%#;<_TW"23@/\+FTXL-U)M!),'PY:;^#"#5R#295.S-JM\8N-R$:_)6X3
MF*L3J\8Y&&>%[+XD0UH" 08%T,RTM&$\(]ED2 #WU,&K-;W2@?/2IQL]:P-L
MD/!^4W\T9U_LNQ\CUM+O<CU@<Z.PNJZY,E$: !V>"'J6[0N],O1G958&?K/-
M]QUA7=LTT5;+CM/"I4_+O3<CLMIT7S$![8X?/,%'9-$ \LF_OLF!!PY7K@#N
MG_$ZMX(Z7GU^>$&@)W?B MWBH=^A"_>'30! $\ENLBM#16H? (2T6IX+'2K0
M *B1IC\<@K>V^VYPG)W?2,T+8_%7C NA0PX<[A6< = -@./9P8)=A^9U%^AH
M +$]'IX3]Z8_Y#0UU3;EA\^J+?*G.?Y1-W!( VA* ++U6[S] [JP_<:*NE\=
M6'(+Z>0T:0#%U#WU;KY!7^9\]17JD1JEEN[(_ N=2C*R]0UKKR_5PI$&L**[
M>QIR:ZS *V=*81W=_3#D!:%?3"TK>[)?H;O4IV9T@+/C)&$:0.4)$M4Z^T?5
M'[2QOUX-/LNSL?>.B3FDK9F'=.?,='LS_W>*SI-WSWT^P7B#*R[2"S^_FN_C
M^P=[F%0^:WR'L\A --8LYTNG63P-T&VG4*P=%=1KQY:#;$RE;)^$<Q^)X< Q
M3KSU7.'7B5PO?C&6K&QI *.4F"47A=[O;DK?R 2?\B#[IX<?7>-B*ML)4B,Q
M,(N<S)D?XWL';H;G(_)E/92P;8Z+W!BRR$FX9I/O]9O_NY=3K]#1)O\/4$L!
M A0#%     @ :3RL4EREAF2G'0  ("P!  T              ( !     &5X
M7S(T,S@T-2YH=&U02P$"% ,4    " !I/*Q2P*Y_"X0#  "2#@  $0
M        @ '2'0  ;6)R>"TR,#(Q,#4Q,BYX<V102P$"% ,4    " !I/*Q2
M8%OV=08%  "2,   %0              @ &%(0  ;6)R>"TR,#(Q,#4Q,E]D
M968N>&UL4$L! A0#%     @ :3RL4OQHYP4Z!@  ,4$  !4
M ( !OB8  &UB<G@M,C R,3 U,3)?;&%B+GAM;%!+ 0(4 Q0    ( &D\K%*Z
MK&Y,H@0  )(Q   5              "  2LM  !M8G)X+3(P,C$P-3$R7W!R
M92YX;6Q02P$"% ,4    " !I/*Q2H,%>&QH.   U5P  $P
M@ $ ,@  ;6)R>#(P,C$P-#(V7SAK+FAT;5!+ 0(4 Q0    ( &D\K%+\)6;_
M4$   (M+   =              "  4M   !M;VQE8W5L:6YL;V=O<F5S:7IE
@9&-L96%R+FIP9U!+!08     !P ' ,\!  #6@      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
